Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

National Cancer Centre, Singapore: Clinical Trials & FDA Approval Profile

National Cancer Centre, Singapore (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (5 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.9%
Median Closed Enrollment vs National (145 pts)37 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Cancer Centre, Singapore
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)12 (5)
Completed vs Stopped Early3 / 1 (5.9%)
Median Closed Actual Enrollment37 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Cancer Centre, Singapore
Hospital Research SiteLocationShared Protocols
National Cancer Centre SingaporeSingapore11
Tan Tock Seng HospitalSingapore3
Seoul National University HospitalSeoul3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Cancer Centre, Singapore
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05377034Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vsPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Centre, Singapore Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI